Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4410-4415
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4410
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4410
Figure 2 Serum glypican-3 levels in 32 liver cirrhosis patients and in 37 hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer-stage A and B.
A: Each dot represents one patient; B: Frequencies of α-fetoprotein (AFP) ≥ 400 μg/L and glypican-3 (GPC3) > 300 ng/L in hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer-stage A and B.
- Citation: Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16(35): 4410-4415
- URL: https://www.wjgnet.com/1007-9327/full/v16/i35/4410.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i35.4410